Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025

A new era in the treatment of aplastic anemia.

View Full Paper
Ask AI
Bookmark
Share

Authors

KHKohei Hosokawa

Discussion

Loading...

Member takes

Overview

This review highlights advancements in immunosuppressive therapy and hematopoietic stem cell transplantation in aplastic anemia.

Key Points

  • The approval of equine ATG in Japan provides a new option for immunosuppressive therapy.
  • Triple combination therapy with ATG, CsA, and thrombopoietin receptor agonists shows promising efficacy.
  • HLA-haploidentical transplantation with post-transplant cyclophosphamide improves safety and efficacy for patients without matched donors.
  • Immunosuppressive therapy includes a range of treatments tailored to the severity of aplastic anemia.

Cite This Study

Kohei Hosokawa (2025) studied this question.

synapsesocial.com/papers/68c24236b210217d647a2602https://doi.org/10.11406/rinketsu.66.572
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A meta-analysis of immunosuppressive and Pharmacological therapies in aplastic anaemia with and without Indigenous equine antithymocyte globulin (eATG)2026 · 7 citations
  2. 2Anti-thymocyte globulin-based treatment frequently leads to enduring treatment success in both old and young adult patients with aplastic anaemia: a real-world analysis from the Dutch aplastic anaemia registry2026
  3. 3Calcineurin inhibitor and eltrombopag combination for acquired aplastic anemia: results from a large national database2025
  4. 4Real-world use of thrombopoietic agents in treatment-naïve children with severe aplastic anemia: a multicenter retrospective study2026
  5. 5Rapid early remission in a patient with severe aplastic anemia: a case report of hetrombopag, cyclosporine, and danazol combination therapy2025